Company intelligence / Profile preview

Fournier

Ownership: Private
Employees: ~4376
Development stage: Other

Overview

Fournier was best known for its fenofibrate-based therapies, especially under the Lipanthyl brand, which became the most-prescribed lipid-lowering medication in Europe by the 1990s. Its lead product fenofibrate was approved in France as early as 1974 and later globally. The company also developed drugs for cardiovascular diseases and urogynecology, including estrogen-replacement systems and anti-ulcer agents. At time of acquisition by Solvay in 2005, it had a robust commercial portfolio with additional pipeline programs targeting cardiovascular and metabolic diseases.

Therapeutic areas: Cardiovascular
Modalities: Small moleculeChemical drugs
Industry: Biotech

Partnerships

Numerous marketing/distribution partnerships worldwidepost-acquisition R&D partnership between Abbott Laboratories and Inventiva regarding former Fournier R&D labs/assets

Beyond the preview

Go deeper on Fournier.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fournier.